NCT05892185 is a NA clinical trial of GELA in Glaucoma, sponsored by Mingche Biotechnology CO., LTD.

Who is sponsoring NCT05892185?

NCT05892185 is sponsored by Mingche Biotechnology CO., LTD.

What drugs are being tested in NCT05892185?

Interventions in NCT05892185: GELA, XEN.

Is NCT05892185 still recruiting?

NCT05892185 is currently status unknown. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT05892185

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Efficacy and Safety of Glaucoma Implant in Primary Open Angle Glaucoma

Status unknown NA Last updated 7 June 2023

What this trial tests

NA trial testing GELA in Glaucoma in 20 participants. Status unknown.

Timeline

31 May 2023

Primary endpoint
12 January 2024

19 July 2024

Quick facts

Lead sponsor	Mingche Biotechnology CO., LTD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	20
Start date	31 May 2023
Primary completion	12 January 2024
Estimated completion	19 July 2024

Drugs / interventions tested

GELA
XEN

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

Mingche Biotechnology CO., LTD

Who can join

Adults 18 to 75, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the efficacy and safety of glaucoma device in the treatment of primary open-angle glaucoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05892185 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mingche Biotechnology CO., LTD
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05892185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing